An Extreme Makeover - Website Edition Blessing
If you have a web site that is 12 years old and you haven't had nearly enough time to keep it up and add info, then the bare spots will show. When I was starting the site, web encoding, HTML, was centered around a now almost forgotten browser, Netscape. Screen sizes were 800x600 if you were lucky. Each Christmas break I would put in a mad rush to update the site to get pages into a more modern era but given I have a career with daily responsibilities, I have fallen behind year by year.
I received e-mails from Paul in Australia the other day. He's up to date on current web coding and has generously offered to help bring the site into the 21st century.
With a new layout, I can again focus on getting better and better content. And that benefits everyone.
I could not think of a better holiday gift.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
